Predict your next investment

Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
iqvia.com

See what CB Insights has to offer

Investments

6

Partners & Customers

10

Service Providers

1

About IQVIA

IQVIA is a global provider of information, technology solutions, and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes.

IQVIA Headquarter Location

4820 Emperor Blvd

Durham, North Carolina, 27703,

United States

866-267-4479

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing IQVIA

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find IQVIA in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

IQVIA Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

IQVIA Rank

Latest IQVIA News

RWD from community registries ads long COVID understanding: IQVIA

Oct 25, 2021

By Jenni Spinner An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research. For most patients diagnosed with COVID-19, the majority of symptoms pass after a week or two. However, a group of patients is dealing with aftereffects for weeks, even months--what the healthcare community calls “long COVID.” The life-sciences industry does not yet understand why some patients get seriously ill from COVID and why others have no symptoms at all, nor what the factors behind long COVID cases are. Nancy Dreyer, epidemiologist and chief scientific officer with IQVIA, spoke with Outsourcing-Pharma about the phenomenon of long COVID, and the resources the research community is turning to in the hopes of gaining wisdom about the condition. OSP: Can you share a slice of what it’s like to be an epidemiologist during COVID-19’s rampage?​ ND: Prior to the COVID-19 pandemic, people often thought that epidemiology referred to skin disease. This pandemic made epidemiology a household name and, in turn, lots of people became “armchair epidemiologists.” Mixed messages about how best to protect ourselves have made it feel like we are also suffering from an epidemic of misinformation. That said, it is extraordinarily difficult to try to control a pandemic. COVID is my third pandemic, and by far, the one with the biggest toll on human life. OSP: Could you please talk about how amassing data from various sources has helped further our understanding of COVID-19, and how the disease impacts patients?​ ND: Real-world data (RWD) is the first line of defense for natural disasters. When we hear of a potential threat, we start counting and looking for patterns. For COVID, we have used hospital records to understand the characteristics of people who present with serious, life-threatening conditions. Additionally, we are using RWD from outpatient ambulatory care visits to understand post-acute sequelae of COVID-19, sometimes called PASC or long COVID. Another factor brought to light by the pandemic is the importance of the voice of the patient, both through systematic research programs like our online study of COVID in the community ​ and through grass-root patient organizations – particularly those formed around long COVID, giving it visibility and shaping the character of this emerging condition. Last, we also see a variety of new data sources that are helping shape our understanding of COVID. For example, in professional sports such as the National Basketball Association (NBA), which has generated important information about disease transmission among people in close quarters, using real-world evidence (RWE) assembled from its “closed campus occupational health program” which ran last year during what we called the “NBA bubble.” They used data from daily lab tests of all participating players, staff, and most vendors, collected before and during campus activities, and were able to study transmission during participation in close contact, unmasked activities. The National Football League (NFL) also studied their players with regular testing and used the information to adjust their COVID management protocols. Their data showed transmission after less than 15 minutes or close interactions. The scientific evidence from these sports leagues was published in prestigious medical journals, including JAMA Internal Medicine, Annals of Internal Medicine, and CDC’s Morbidity and Mortality Weekly Report, living proof of the value of diverse RWE and how various sources can make important contributions to aspects of interest. OSP: What exactly is ​long COVID? What are the most common persistent symptoms patients are still struggling with months out?​ Nancy Dreyer, chief scientific officer, IQVIA ND: The Centers for Disease Control and Prevention (CDC) typically talk about long COVID in terms of symptoms that last more than 4 weeks after being infected with COVID. Symptoms seem to be a combination of exhaustion and severe fatigue often coupled with respiratory problems, brain fog, heart palpitations, joint or muscle pain, and diarrhea. Additionally, there are multiorgan effects or autoimmune conditions that persist over a longer time with symptoms lasting weeks or months after COVID illness. Multiorgan effects can impact many, if not all, body systems, including heart, lung, kidney, skin, and brain functions. While long COVID seems to be quite real, we also see some similar symptoms among the uninfected that likely reflect the toll of the pandemic experience on the population. An example is depression that may stem from or be aggravated by prolonged isolation – a condition that is independent of having been infected with COVID. OSP: You mention that the medical community is struggling to understand why some folks get severe symptoms and some none at all, and why some come out on the other side with no lingering effects, and others have severe, persistent after-effects. Could you please talk about that journey and how progress might be made?​ ND: Scientific discovery is a journey that advances through conjecture and refutation. Researchers produce ideas, test them, and, if they find something of interest, investigate whether it is also evident in other populations. General statements about nature come from findings that are not limited to one time and place. Causal mechanisms should be repeatable in different populations, and when you see similar findings in those different populations, it adds credence to the findings. As with every disease, some people are more vulnerable than others. For COVID, we looked first for quick fixes. For example, there were suggestions that vitamin D would protect people from COVID, as well as anti-ulcer over-the-counter (OTC) medications and daily antihistamine use. None of these hypotheses have panned out so far in our studies, but there may be protective benefits of some of these supplements when used in combination with other factors we have not yet identified. We are still in the early stages of the search for why some people get sick and why others do not. We found that people with autoimmune disorders are at higher risk of getting very sick from COVID. They are 30% more likely to have severe symptoms during the acute phase of the infection, and more than twice as likely to report persistent, debilitating symptoms of COVID-19, such a shortness of breath and fatigue, than other study participants. Also, people with hypertension report more symptoms and more serious COVID symptoms, even 30 days after having tested positive for COVID. It is also important to note what we are not​ seeing. In our community-based work, African Americans have reported substantially fewer symptoms and serious symptoms than white patients. Additionally, diabetics do not appear to have more or worse symptoms than others with COVID, a theory that was once proposed after an early high-profile movie star who was diabetic tested positive for COVID early in the pandemic. OSP: Could you please talk about how RWD and/or RWE [please feel free to talk about one or both, whichever you feel appropriate] are helping gain insights into COVID? Specifically, how have community-based registries helped?​ ND: Most of what we have learned about COVID has come from RWD. This is not intended to diminish the value of randomized controlled trials (RCTs), but apart from rare platform trials like those conducted by the UK National Health Service, it takes a long time to set up a trial, enroll people, conduct and complete the study. And by their very design, they are quite costly. The CARE project ​ is a voluntary, unpaid online study that has more than 30,000 participants who are contributing information about their experience with COVID and the COVID vaccine. We continue to recruit people who have been tested for COVID, no matter what the results, or who have been vaccinated – so the study is open to just about any adult in the US. This represents the bulk of adult human experience with COVID in the US since most people are not going to health care facilities for COVID unless they are extremely ill.  We are working to leverage these data to understand how to mitigate risk. Example questions we want to be answered include: Is there anything that will help us be more resistant to COVID? Who is at the highest risk? How are most people affected by the vaccine? Does it knock them out for days? Do they miss work? Should they plan to get childcare coverage because they can’t take care of themselves and their families? Does everybody react the same way or are some people more likely to suffer side effects? OSP: Can you share ways in which IQVIA technologies and efforts have specifically helped further our COVID understanding?​ ND: We are leveraging IQVIA technology to collect information directly from the public about COVID. Patient-generated health data (PGHD) needs to be handled differently than traditional data collection from clinicians or health systems. That being said, it is an art to communicate in a way that regular people without medical training can understand and respond to, and to know when clinical validation is needed versus when a patient-reported outcome is sufficient. As we accumulate more information, big data, artificial intelligence, and machine learning will be important tools to look for patterns that may not be immediately noted. Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

IQVIA Investments

6 Investments

IQVIA has made 6 investments. Their latest investment was in Kairos as part of their Secondary Market on March 3, 2021.

CBI Logo

IQVIA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/1/2021

Secondary Market

Kairos

Yes

1

12/18/2019

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/4/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/1/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/19/2018

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/1/2021

12/18/2019

10/4/2019

7/1/2019

7/19/2018

Round

Secondary Market

Series C

Series A

Series B

Series A - II

Company

Kairos

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

IQVIA Acquisitions

9 Acquisitions

IQVIA acquired 9 companies. Their latest acquisition was Q2 Solutions on April 01, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/1/2021

$991

Acquired

2

2/12/2019

Subscribe to see more

$99M

Subscribe to see more

10

5/1/2018

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2017

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

2/21/2017

Recap

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

4/1/2021

2/12/2019

5/1/2018

10/16/2017

2/21/2017

Investment Stage

Acq - Fin

Private Equity

Recap

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

IQVIA Partners & Customers

10 Partners and customers

IQVIA has 10 strategic partners and customers. IQVIA recently partnered with Nview Health on April 4, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

4/23/2021

Partner

Nview Health

United States

3/1/2021

Partner

Strados Labs

United States

1/1/2021

Partner

FeetMe

France

12/16/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/2/2020

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/23/2021

3/1/2021

1/1/2021

12/16/2020

11/2/2020

Type

Partner

Partner

Partner

Partner

Client

Business Partner

Nview Health

Strados Labs

FeetMe

Country

United States

United States

France

Subscribe to see more

Subscribe to see more

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

10

10

IQVIA Service Providers

1 Service Provider

IQVIA has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Merger

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Merger

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

IQVIA Team

43 Team Members

IQVIA has 43 team members, including current President, Senior Vice President, Prasanna Pitale.

Name

Work History

Title

Status

Prasanna Pitale

President, Senior Vice President

Current

Gillian Corken

Chief Executive Officer

Former

Ferzaan Engineer

Chief Executive Officer

Former

Naz Haji

Chief Executive Officer, Chief Information Officer, Senior Vice President

Former

Dieter Jagodzinska

Chief Executive Officer

Former

Name

Prasanna Pitale

Gillian Corken

Ferzaan Engineer

Naz Haji

Dieter Jagodzinska

Work History

Title

President, Senior Vice President

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer, Chief Information Officer, Senior Vice President

Chief Executive Officer

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.